X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23) 23
humans (15) 15
oncology (14) 14
cancer (13) 13
lymphocytes (13) 13
breast cancer (12) 12
biomarkers (11) 11
female (11) 11
animals (10) 10
immunotherapy (9) 9
mice (9) 9
cell biology (8) 8
article (6) 6
cell line, tumor (6) 6
pathology (6) 6
tumors (6) 6
breast neoplasms - drug therapy (5) 5
xenograft model antitumor assays (5) 5
acquired-resistance (4) 4
biopsy (4) 4
breast neoplasms - genetics (4) 4
breast neoplasms - metabolism (4) 4
breast neoplasms - pathology (4) 4
clinical trials (4) 4
expression (4) 4
gene expression (4) 4
genes (4) 4
immunohistochemistry (4) 4
inhibition (4) 4
inhibitors (4) 4
lymphocytes t (4) 4
medical research (4) 4
medicine, research & experimental (4) 4
pd-1 blockade (4) 4
receptor, erbb-2 - antagonists & inhibitors (4) 4
research (4) 4
resistance (4) 4
tumor-infiltrating (4) 4
activation (3) 3
amplification (3) 3
cancer and oncology (3) 3
cancer och onkologi (3) 3
chemical and pharmacologic phenomena (3) 3
clinical medicine (3) 3
combination (3) 3
cytotoxicity (3) 3
deoxyribonucleic acid--dna (3) 3
drug resistance (3) 3
drug resistance, neoplasm - genetics (3) 3
gene expression regulation, neoplastic - drug effects (3) 3
genetics (3) 3
growth-factor receptor (3) 3
her2 (3) 3
immune checkpoint (3) 3
kinase (3) 3
kinases (3) 3
klinisk medicin (3) 3
ligands (3) 3
medical and health sciences (3) 3
medicin och hälsovetenskap (3) 3
metastases (3) 3
metastasis (3) 3
mutations (3) 3
patients (3) 3
receptor, erbb-2 - genetics (3) 3
receptor, erbb-2 - metabolism (3) 3
receptor, fibroblast growth factor, type 1 - genetics (3) 3
receptors, estrogen - metabolism (3) 3
tumour biomarkers (3) 3
adult (2) 2
aged (2) 2
algorithms (2) 2
antigen presentation (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
apoptosis (2) 2
biomarkers, tumor - analysis (2) 2
cancer patients (2) 2
carcinoma (2) 2
care and treatment (2) 2
cd8 antigen (2) 2
cell activation (2) 2
cell death (2) 2
cell survival (2) 2
cells (2) 2
chemotherapy (2) 2
cyclin d1 - metabolism (2) 2
disease models, animal (2) 2
double-blind (2) 2
drug resistance, neoplasm - drug effects (2) 2
erbb-2 protein (2) 2
estrogen-receptor (2) 2
fgfr (2) 2
fibroblast growth factor receptor 1 (2) 2
fibroblast growth factor receptors (2) 2
fulvestrant (2) 2
fulvestrant - administration & dosage (2) 2
fulvestrant - pharmacology (2) 2
gene (2) 2
gene amplification (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 248 - 11
Journal Article
Nature Communications, ISSN 2041-1723, 12/2019, Volume 10, Issue 1, pp. 1373 - 14
Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance.... 
Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Cyclin D1 - metabolism | Receptors, Estrogen - metabolism | Circulating Tumor DNA - genetics | Humans | Purines - administration & dosage | Fulvestrant - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Quinolines - pharmacology | Breast Neoplasms - metabolism | Quinoxalines - pharmacology | MCF-7 Cells | Fulvestrant - administration & dosage | Female | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyrazoles - pharmacology | Aminopyridines - administration & dosage | Antineoplastic Agents, Hormonal - pharmacology | Signal Transduction | Purines - pharmacology | Antineoplastic Agents, Hormonal - administration & dosage | Proportional Hazards Models | Breast Neoplasms - drug therapy | Piperazines - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Naphthalenes - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aminopyridines - pharmacology | Progression-Free Survival | High-Throughput Nucleotide Sequencing | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Mutation | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Drug Resistance, Neoplasm - drug effects | Tyrosine | Xenotransplantation | Clinical trials | Antagonists | Breast cancer | Drug resistance | Patients | Cyclin-dependent kinase 4 | Fulvestrant | Gene sequencing | Amplification | Next-generation sequencing | Inhibitors | Xenografts | Open reading frames | Fibroblast growth factor receptor 1 | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | DNA sequencing | Cancer | Fibroblast growth factor receptors
Journal Article
Histopathology, ISSN 0309-0167, 01/2018, Volume 72, Issue 2, pp. 342 - 350
Journal Article
NATURE MEDICINE, ISSN 1078-8956, 08/2019, Volume 25, Issue 8, pp. 1243 - 1243
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2019, Volume 14, Issue 6, p. e0218458
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4323 - 4334
Purpose: Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant... 
COMBINATIONS | MULTICENTER | TRASTUZUMAB | ONCOLOGY | CCND1 AMPLIFICATION | GROWTH | ACQUIRED-RESISTANCE | OPEN-LABEL | PERTUZUMAB | KINASE INHIBITOR LAPATINIB | ERBB RECEPTORS | Receptor, ErbB-2 - genetics | Humans | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Antibodies, Monoclonal, Humanized - administration & dosage | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Gene Expression Regulation, Neoplastic - drug effects | Lapatinib | Fibroblast Growth Factor 3 - antagonists & inhibitors | Fibroblast Growth Factor 3 - genetics | Antineoplastic Combined Chemotherapy Protocols | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Xenograft Model Antitumor Assays | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Neoadjuvant Therapy - adverse effects | Mice | Drug Resistance, Neoplasm - drug effects | Tyrosine | Fibroblast growth factor 3 | Phosphorylation | Statistical analysis | Copy number | Breast cancer | Statistical methods | Kinases | Gene expression | Patients | ErbB-2 protein | Fibroblast growth factor 4 | Amplification | Signaling | Gene amplification | Inhibitors | Experimental design | Xenografts | Fibroblast growth factor receptor 1 | Protein-tyrosine kinase | Trastuzumab | Tumors | Cancer | Fibroblast growth factor receptors | trastuzumab | breast cancer | drug resistance | HER2 | FGFR
Journal Article
Molecular and Cellular Proteomics, ISSN 1535-9476, 10/2017, Volume 16, Issue 10, pp. 1705 - 1717
Journal Article
Journal Article
Journal Article
NPJ BREAST CANCER, ISSN 2374-4677, 09/2019, Volume 5, Issue 1, pp. 1 - 9
Clinical trials have demonstrated the efficacy of combining phosphoinositide 3-kinase (PI3K) inhibitors with endocrine therapies in hormone therapy-refractory... 
HORMONE-RECEPTORS | PICTILISIB | ONCOLOGY | PHASE IB | PATHWAY | GENES | DOUBLE-BLIND | PTEN | MUTATIONS | PI3K INHIBITOR | Biomarkers | Breast cancer | Metastasis | Mutation | Tumors
Journal Article
Cancer Research, ISSN 0008-5472, 04/2018, Volume 78, Issue 7, pp. 1845 - 1858
Small-molecule inhibitors of the mTORC2 kinase (torkinibs) have shown efficacy in early clinical trials. However, the torkinibs under study also inhibit the... 
TARGET | ACTIVATION | PROTEIN-KINASE-B | MECHANISM | ONCOLOGY | PRECLINICAL MODELS | PHOSPHORYLATION | RESISTANCE | HYDROPHOBIC CONTENT | RICTOR | SIRNA DELIVERY | Cell Survival - drug effects | RNA, Small Interfering - genetics | Humans | RNA, Small Interfering - pharmacology | Receptor, ErbB-2 - metabolism | Triple Negative Breast Neoplasms - drug therapy | Lapatinib - pharmacology | Nanoparticles | Xenograft Model Antitumor Assays | Animals | Rapamycin-Insensitive Companion of mTOR Protein - genetics | Mice, Nude | Triple Negative Breast Neoplasms - pathology | Female | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Mechanistic Target of Rapamycin Complex 2 - antagonists & inhibitors | Disease Models, Animal | TOR protein | Phosphorylation | Intravenous administration | Clinical trials | AKT protein | mRNA | Kinases | Autophagy | Negative feedback | Inhibition | Medical research | Enzymes | Cell survival | RNA-mediated interference | Feasibility studies | Breast cancer | Survival | Ablation | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Inhibitors | In vivo methods and tests | Nanotechnology | Phagocytosis | Tumors | Cancer | mTOR | Rictor | RNA interference | Breast Cancer | Nanomedicine
Journal Article
Genome medicine, ISSN 1756-994X, 07/2019, Volume 11, Issue 1, pp. 50 - 3
It was highlighted that the original article [1] contained a typesetting mistake in the name of Noel Filipe da Cunha Carvalho de Miranda. This was incorrectly... 
Journal Article
by Hendry, Shona and Salgado, Roberto and Gevaert, Thomas and Russell, Prudence A and John, Tom and Thapa, Bibhusal and Christie, Michael and van de Vijver, Koen and Estrada, M.V and Gonzalez-Ericsson, Paula I and Sanders, Melinda and Solomon, Benjamin and Solinas, Cinzia and Van den Eynden, Gert G.G.M and Allory, Yves and Preusser, Matthias and Hainfellner, Johannes and Pruneri, Giancarlo and Vingiani, Andrea and Demaria, Sandra and Symmans, Fraser and Nuciforo, Paolo and Comerma, Laura and Thompson, E.A and Lakhani, Sunil and Kim, Seong-Rim and Schnitt, Stuart and Colpaert, Cecile and Sotiriou, Christos and Scherer, Stefan J and Ignatiadis, Michail and Badve, Sunil and Pierce, Robert H and Viale, Giuseppe and Sirtaine, Nicolas and Penault-Llorca, Frederique and Sugie, Tomohagu and Fineberg, Susan and Paik, Soonmyung and Srinivasan, Ashok and Richardson, Andrea and Wang, Yihong and Chmielik, Ewa and Brock, Jane and Johnson, Douglas B and Balko, Justin and Wienert, Stephan and Bossuyt, Veerle and Michiels, Stefan and Ternes, Nils and Burchardi, Nicole and Luen, Stephen J and Savas, Peter and Klauschen, Frederick and Watson, Peter H and Nelson, Brad H and Criscitiello, Carmen and O’Toole, Sandra and Larsimont, Denis and de Wind, Roland and Curigliano, Giuseppe and André, Fabrice and Lacroix-Triki, Magali and van de Vijver, Mark and Rojo, Federico and Floris, Giuseppe and Bedri, Shahinaz and Sparano, Joseph and Rimm, David and Nielsen, Torsten and Kos, Zuzana and Hewitt, Stephen and Singh, Baljit and Farshid, Gelareh and Loibl, Sibylle and Allison, Kimberly H and Tung, Nadine and Adams, Sylvia and Willard-Gallo, Karen and Horlings, Hugo M and Gandhi, Leena and Moreira, Andre and Hirsch, Fred and Dieci, Maria V and Urbanowicz, Maria and Brcic, Iva and Korski, Konstanty and Gaire, Fabien and Koeppen, Hartmut and Lo, Amy and Giltnane, Jennifer and Rebelatto, Marlon C and Steele, Keith E and Zha, Jiping and Emancipator, Kenneth and Juco, Jonathan W and Denkert, Carsten and Reis-Filho, Jorge and Loi, Sherene and Fox, Stephen B
Advances In Anatomic Pathology, ISSN 1072-4109, 11/2017, Volume 24, Issue 6, pp. 311 - 335
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as... 
cancer | lymphocytes | pathology | biomarkers | tumor-infiltrating | immunotherapy | CUTANEOUS MALIGNANT-MELANOMA | TERTIARY LYMPHOID STRUCTURES | NONPOLYPOSIS COLORECTAL-CANCER | MICROSATELLITE INSTABILITY | MISMATCH-REPAIR | RELAPSE-FREE SURVIVAL | LIGAND 1 EXPRESSION | REGULATORY T-CELLS | VERTICAL GROWTH-PHASE | INDEPENDENT PROGNOSTIC-FACTOR
Journal Article